Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05546723 · ClinicalTrials.gov registry record · Phase 1
LMY-920 for Treatment of Relapsed or Refractory Myeloma
A Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Luminary Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05546723 is a Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory that is actively recruiting participants, run by Luminary Therapeutics. The registered enrollment target is 30 participants, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05546723, a Phase 1 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, is actively recruiting participants, sponsored by Luminary Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Conditions Studied
Interventions
- BIOLOGICAL Autologous CAR-T cell therapy expressing the BAFF-ligand.
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05546723
The ClinicalTrials.gov registry entry for NCT05546723 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (39% lower). The listed sponsor is Luminary Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 1 intervention - of which Autologous CAR-T cell therapy expressing the BAFF-ligand. is the first listed.
NCT05546723 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05546723 about?
NCT05546723 is a clinical study titled "LMY-920 for Treatment of Relapsed or Refractory Myeloma". Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be ...
What is the current status of trial NCT05546723?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-03-13. Estimated completion is 2025-10-31.
What conditions does trial NCT05546723 study?
This clinical trial studies the following conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.
What interventions are being tested in trial NCT05546723?
The interventions under investigation include: Autologous CAR-T cell therapy expressing the BAFF-ligand. (BIOLOGICAL).
Who is sponsoring clinical trial NCT05546723?
This trial is sponsored by Luminary Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05546723 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
RECRUITING · Phase 1
-
Ixazomib + Pomalidomide + Dexamethasone In MM
ACTIVE NOT RECRUITING · Phase 1
-
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
ACTIVE NOT RECRUITING · Phase 1
-
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
COMPLETED · Phase 1
-
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.